Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market
- 2020年04月24日 19:37:00
- テクノロジー
- JCN Newswire
Efficient R&D Platform and Strong R&D Strength
The Company is dedicated to finding solutions to treat tumors and immunological diseases. It is generally known that it takes years to develop a new drug. However, the Company has over 20 drug development programs developed in-house though it has been established for only eight years. These programs include 12 antibodies in clinical-stage development, six bi-specific antibodies (two of which are at the clinical stage), and four antibodies with IND approvals from the Food and Drug Administration (FDA). Its product pipelines cover several major diseases, such as tumors, immunological diseases, and cardiovascular diseases. It is worth mentioning that the Company has developed all its programs in-house. In November 2015, the Company became the first China-based biotech company to out-license a fully internally discovered monoclonal antibody to a world-leading pharmaceutical company as it out-licensed its CTLA-4 monoclonal antibody drug candidate (AK107) to Merck for a total consideration of up to USD200 million.
The Company's strong R&D capability is indispensable from its end-to-end ACE Platform that possesses comprehensive, the most cutting-edge functionalities in developing therapeutic antibodies. The ACE Platform encompasses drug development and manufacturing and enables seamless technology transfer from drug discovery and CMC to manufacturing. Moreover, it holds strong internal manufacturing capacity that is compliant with GMP standards regulated by the NMPA, FDA and EMA. All drugs in the clinical stage are produced in the Company's proprietary facilities in line with GMP standards.
Prominent Advantages of Core Products, Favored by the Capital Market
The key to biopharmaceutical success lies in R&D strength and efficiency. The player who takes the lead to develop a drug and obtain approval for launch, and who can prove commercialization capabilities will gain competitive edges.
The Company has developed industry-leading drugs with the ACE Platform including its core products: PD-1/CTLA-4 bi-specific antibody (AK104) and PD-1 monoclonal antibody drug, Penpulimab (AK105). Its products also encompass AK101, a promising monoclonal antibody against autoimmune diseases, and AK102 that has high potential to become the first cardiovascular drug candidate against PCSK9 developed in China.
The Company has led the world in terms of the R&D of bi-specific antibodies. Bi-specific antibodies are deemed as a second-generation antibody therapy against tumors. With respect to the research on bi-specific antibodies, the Company possesses the unique bifunctional antibody technology, Tetrabody, making it one of the few bi-specific antibody platforms verified in both manufacturing and clinical stage. According to clinical observation, compared with the combined therapy of Nivolumab and Ipilimumab, AK104 has demonstrated better safety and efficacy. As of September 30, 2019, over 90 bi-specific antibodies were undergoing clinic trial. Nevertheless, no PD-(L)-based bi-specific antibodies had been approved for market launch. AK104 is the world's first bi-specific antibody drug that is in the clinical trial stage. It is expected that the first new drug application (NDA) of AK104 of the Company for treating cervical cancer will result in first-mover advantage.
AK105 of the Company is a monoclonal antibody currently in late-stage clinical development. PD-1 monoclonal antibody drugs are experiencing fierce competition, as six PD-1 drugs have been launched in China. Despite the extensively competitive market, AK105 is still favored for its strong efficacy and high safety. Therefore, Sino Biopharmaceutical Limited, a HK-listed pharmaceutical leader, has cooperated with the Company to jointly develop and commercialize AK105. AK105 of the Company is the only PD-1 antibody that Sino Biopharm can use to develop PD-1-based monotherapy or combination therapy, which evidences the great commercial potential of AK105. After the new drug is launched, the wide online sale channels and immense commercial capability of Sino Biopharmaceutical Limited will be utilized by the Company to maximize the commercial value of AK105.
Thanks to its strong R&D strength and commercialization capabilities, the Company has been favored by the capital market. Through Series D financing in November last year, the Company raised USD126 million in total, with the leading investor being Sino Biopharmaceutical Limited. Medical funds like Lake Bleu Capital, OrbiMed, and AIHC Capital participated in the financing. The Company's valuation reached USD836 million after Series D financing and became nearly 18 times as high as that after Series A financing of RMB330 million in just four years. Especially, Shenzhen Capital Group Co., Ltd. (SCGC), a leading venture capital firm in China that was co-founded by the Shenzhen Municipal Government and a group of private partners, participated in every series of financing. Relevant funds under K. Wah Group became a shareholder of Akeso in the series of financing before the IPO. This also means that K. Wah Group has set foot in the healthcare sector. Investment from famous capital holders reflect Akeso's bright future.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
ボイド・ワターソンとアンバー・インフラストラクチャー、共同で戦略的取引を発表
Rソシエダードが左ウイング補強でガラタサライのトルコ代表FWアクトゥルコールを獲得候補に
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
喫煙者の4分の3がベイプについて誤解、新たな世論調査で判明
松本潤が独立前にファンへメッセージ 事務所最後の仕事、京セラドーム公演終え 嵐は契約継続
日鉄とUSスチール、米国除く全ての規制当局から買収を承認と発表
【日本ハム】今季9度目の零封勝ち「気持ちよかった」新庄監督「6番投手山崎福也」大当たり
たけうちほのか、兄竹内涼真は「飲んだらウザい」特定の話題になると「私帰ります」
博多大吉「飲み始めは朝10時30分から」NHK「あさイチ」終わりにコンビでお酒
宮迫博之が5年ぶりの地上波出演を動画で報告も、千葉テレビが完全否定「当番組の放送はありません」
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
柏原崇(45)現在を調べてみた結果、相変わらずかっこよすぎた!
大原櫻子、ガーシー暴露後初のSNS投稿に賛否の声「イメージ最悪になった」
「暴露します」松本人志飲み会参加セクシー女優「衝撃作」発売「言えなくてずっと溜めてた」
漫才師の今くるよさん死去 膵がんのため
大谷翔平被弾投手が悪態ついて退場処分!次打者フリーマンと対戦中に判定巡り塁審と口論
金正恩の妹・金与正関連のネタ投稿がTwitterで大量に出回る
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
トータス松本めぐる報道、所属事務所が謝罪「本人も社会的責任を痛感」代表取締役も辞任
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
元めちゃイケメンバーの三中元克(32)現在は何をしているのか調べてみた!
柏原崇(45)現在を調べてみた結果、相変わらずかっこよすぎた!
ヒカル、浮気相手とのLINE流出にドン引きの声「キモすぎる」「吐きそう」
ガーシーが綾野剛のLINE公開でネット騒然「ショック」「すごいエンタメ」
TikTokを賑わす「フエラムネごめんなサイダー味」がセブンイレブンで再販!じゅるるマスカットも買うなら今!
完全にダマされた! 『ラヴィット!』あのちゃん“事故レベル”大暴走は『水ダウ』遠隔操作のしわざだった ネットも納得
ボイド・ワターソンとアンバー・インフラストラクチャー、共同で戦略的取引を発表
Rソシエダードが左ウイング補強でガラタサライのトルコ代表FWアクトゥルコールを獲得候補に
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
喫煙者の4分の3がベイプについて誤解、新たな世論調査で判明
松本潤が独立前にファンへメッセージ 事務所最後の仕事、京セラドーム公演終え 嵐は契約継続
日鉄とUSスチール、米国除く全ての規制当局から買収を承認と発表
【日本ハム】今季9度目の零封勝ち「気持ちよかった」新庄監督「6番投手山崎福也」大当たり
たけうちほのか、兄竹内涼真は「飲んだらウザい」特定の話題になると「私帰ります」
【市場反応】米4月中古住宅販売成約指数、予想下回りドル上値重い
博多大吉「飲み始めは朝10時30分から」NHK「あさイチ」終わりにコンビでお酒